Tests radiotherapy or surgery with intense hormone therapy for prostate cancer
Tests radiotherapy or prostate removal with hormone therapy in newly diagnosed metastatic prostate cancer.
Plain-language title generated from the registry record
Registry title: Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
Key facts
- Where
- Nanjing, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06992232, who can take part
Where in China
- Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing UniversityNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Trial code
- NCT06992232
- Record updated
- 28 May 2025
- Original description
This multi-center randomized controlled phase II trial was carried out in several hospitals in China to evaluate the efficacy and safety of radiotherapy or radical prostatectomy combined with intense androgen deprivation therapy for newly diagnosed metastatic prostate cancer.Read full original descriptionShow less
Radiotherapy or Radical Prostatectomy Combined With Intense Androgen Deprivation Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multi-center Randomized Controlled Phase II Trial
This multi-center randomized controlled phase II trial was carried out in several hospitals in China to evaluate the efficacy and safety of radiotherapy or radical prostatectomy combined with intense androgen deprivation therapy for newly diagnosed metastatic prostate cancer.
Inclusion: Histologically or cytologically confirmed prostate adenocarcinoma, with distant metastasis diagnosed by novel imaging modalities (PSMA PET/CT or PSMA PET/MR), involving ≤10 metastatic sites (amenable to local therapy) and without visceral metastasis; The primary lesion is deemed resectable, or can achieve a resectable state following IADT; Non-castration range (≥50 ng/dl), or the duration of testosterone levels in the castration range is no more than 3 months; Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 1; Patients must have adequate hematologic function, hepatic function and renal function; Patients must participate voluntarily and sign an informed consent form(ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol; Fertile patients must be willing to use highly effective contraception during the study period.
Exclusion: Patients who had previously received androgen deprivation therapy (including medical or surgical castration) for more than 3 months, or had undergone focal therapy for prostate cancer, or had received radiotherapy or chemotherapy for prostate cancer; Patients with severe or uncontrolled underlying diseases who could not tolerate surgery or radiotherapy; Patients with New York Heart Association (NYHA) Class III/IV congestive heart failure, unstable angina, or a history of myocardial infarction within the past 6 months; Uncontrolled severe hypertension, persistently uncontrolled diabetes, oxygen-dependent pulmonary disease, chronic liver disease, or HIV infection; Within the past 5 years, having had other malignant tumors except for prostate cancer, with the exception of cured basal or squamous cell skin cancer; Suffering from mental illness, mental disability, or being incapable of providing informed consent; Patients with prostatic histopathology exhibiting neuroendocrine, small cell, or sarcomatoid features; The researchers assessed the primary lesion as unresectable.